Pharmacokinetics and safety of brensocatib in patients with cystic fibrosis

Cystic fibrosis in adults

Chair(s): Andrea Gramegna, Pilar Azevedo

Session type: Oral presentation

Ariel Teper

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - A novel treatment for chronic P. aeruginosa pulmonary infection in CF subjects - A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study to evaluate phage therapy

Urania Rappo

Replay

Poster

Abstract

Slides

The cellular immune landscape in end-stage cystic fibrosis lungs

Astrid Vermaut

Replay

Poster

Abstract

Slides

Characterisation of the CF sputum proteome reveals that innate host defence proteins are depleted in frequent exacerbators

Claire Houston

Replay

Poster

Abstract

Slides

Pharmacokinetics and safety of brensocatib in patients with cystic fibrosis

Ariel Teper

Replay

Poster

Abstract

Slides

Interim results from a post-marketing observational safety study (PASS) of levofloxacin inhalation solution in patients with cystic fibrosis

Nicholas Simmonds

Replay

Poster

Abstract

Slides

Economic impact using a virtual model of care in Cystic Fibrosis

Paola Iacotucci

Replay

Poster

Abstract

Slides

Cluster analysis explains heterogeneity in response to elexacaftor/tezacator/ivacaftor in people with cystic fibrosis

Federica Bellino

Replay

Poster

Abstract

Slides

Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy (ETI) for one-year and changes in structural lung disease in people with CF (pwCF)

Shahid Sheikh

Replay

Poster

Abstract

Slides

Eradication of Nontuberculous Mycobacteria in people with Cystic Fibrosis treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study

Inbal Golan-tripto

Replay

Poster

Abstract

Slides

Comorbidities in adult patients with Cystic Fibrosis (CF)

Almudena Felipe Montiel

Replay

Poster

Abstract

Slides

Discussion and Q&A

The ERS International Congress 2023, Milan

#{title}